Media

June 5, 2023 | In the News
GLOBES: Elicio Therapeutics reports positive interim results from a Phase 1 trial at risk of relapse after surgery or chemotherapy.
June 5, 2023 | In the News
BIOTECH TV: Anirban Maitra and Shubham Pant from MD Anderson tell us what targets and approaches look promising in pancreatic cancer.
June 3, 2023 | Publication

O’Reilly EM, Wainberg ZA, Weekes CD, et al.
Presented at the American Society of Clinical Oncology Annual Meeting
June 2-6, 2023
Chicago, IL

June 2, 2023 | In the News
MARKETWATCH: Shares of Elicio Therapeutics were trading higher on the Nasdaq Friday, following the combination of the company with Angion Biomedica.
June 2, 2023 | In the News
PRECISION MEDICINE ONLINE: Elicio Therapeutics on Thursday said it closed a previously announced reverse merger with Angion
April 6, 2023 | In the News
LABIOTECH: Elicio Therapeutics specializes in immunotherapeutic research in the field of cancer and infectious diseases. And its amphiphile technology (AMP) platform is the foundation for the various vaccine candidates in its pipeline, against cancer and other diseases. 
January 31, 2023 | In the News
PHARMA'S ALMANAC: I’ve seen two areas within oncology in particular that have grown significantly with revolutionary potential in the coming year: therapeutics targeting KRAS mutations and the re-emergence of cancer vaccines. Christopher Haqq, MD, PhD
January 17, 2023 | In the News
MED CITY NEWS: Elicio Therapeutics dipped its toe in the IPO waters but decided to go public by merging with publicly traded Angion Biomedica. Clinical-stage Elicio is developing immunotherapies, including cancer vaccines, that work by targeting immune cells located in the lymph nodes.
November 9, 2022 | In the News
BUSINESS OF BIOTECH PODCAST: Chief Scientific Officer Peter DeMuth, PhD at Elicio HQ in Boston talks about how the platform works, and how it's driving rapid clinical progress for the company's robust pipeline of therapeutic vaccines in oncology.